Book a demo

Chemical intelligence powered by cypris.ai

Dns-lysine

(2S)-2-amino-6-[[5-(dimethylamino)naphthalen-1-yl]sulfonylamino]hexanoic acid · also: dansyllysine, epsilon-dansyllysine, Nepsilon-Dansyl-L-lysine, n-epsilon-dansyl-l-lysine, N epsilon -Dansyl-L-lysine

FormulaC18H25N3O4S
Mol. weight379.475
PubChem CID121945
InChIKeyVQPRNSWQIAHPMS-HNNXBMFYSA-N
SMILESCN(C)C1=CC=CC2=C1C=CC=C2S(=O)(=O)NCCCC[C@@H](C(=O)O)N
461Patents
29Research papers
15Patents - last 3 years
0Papers - last 3 years

Who owns the IP

The organizations most actively patenting around this compound, ranked by referenced patent volume.

#AssigneePatents
1Promega Corp102
2Xerox Corp56
3New York Blood Center20
4University of Massachusetts Chan Medical School17
5Kreatech Biotechnology BV12
6Boston University11
7Yissum Research Development Co of Hebrew University of Jerusalem8
8Bausch Health Ireland Ltd7
9Boston Children's Hospital7
10Eastman Kodak Co7

Explore the full landscape

This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.

Visit Cypris

Where innovation is concentrated

Patent classifications ranked by volume reveal the technical domains with the most active filing.

#CodeAreaPatents
1G01NInvestigating / analysing materials221
2C12NMicroorganisms, enzymes140
3C07KPeptides136
4A61KMedicinal preparations123
5C12QMeasuring/testing involving enzymes109
6A61PTherapeutic activity (drug indications)87
7Y10SCross-reference (legacy)77
8C12YEnzyme nomenclature (EC numbers)70
9C07DHeterocyclic compounds64
10C07FOrganometallic compounds45

AI mapped opportunity space

This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.

See Cypris in action

Where research is gaining momentum

Research themes ranked by publication activity show where scientific interest is accelerating around this compound.

#Research topicPapers
1Lipid Membrane Structure and Behavior1
2Monoclonal and Polyclonal Antibodies Research1
3Ultrasound and Hyperthermia Applications1

Who's driving the science

The most-published authors working with this compound, alongside their primary affiliations.

#AuthorAffiliationPapers
1George M. HahnStanford University8
2Glenn C. RiceStanford University7
3George A. FisherStanford University4
4John P. LovejoyCalifornia Institute for Medical Research4
5Yoji ArataWater Research Institute4
6Gillian M. K. HumphriesCalifornia Institute for Medical Research3
7Ichio ShimadaThe University of Tokyo3
8Koichi KatoNagoya City University3
9Robin L. AndersonStanford University3
10Shiao Y. WooStanford University3

Research leaders

This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.

See Cypris in action

The literature that defines it

The most-cited papers anchoring the scientific record for this compound.

Frequently asked questions

Common questions about this compound's patent and research landscape, answered from the underlying data.

What is the molecular formula and weight of Dns-lysine?

Dns-lysine has the molecular formula C18H25N3O4S and a molecular weight of 379.475 g/mol. Its canonical IUPAC name is (2S)-2-amino-6-[[5-(dimethylamino)naphthalen-1-yl]sulfonylamino]hexanoic acid.

Which organization holds the most patents involving Dns-lysine?

Promega Corp holds the largest patent portfolio related to Dns-lysine, with 102 patents. This is followed by Xerox Corp with 56 patents and New York Blood Center Inc with 20 patents.

What are the main patent classification areas for Dns-lysine technologies?

The leading CPC patent subclasses are G01N (221 patents), C12N (140 patents), and C07K (136 patents), indicating concentration in analytical instruments, biotechnology processes, and organic chemistry applications.

What research topics have been published about Dns-lysine?

Published research on Dns-lysine includes studies on Lipid Membrane Structure and Behavior and Monoclonal and Polyclonal Antibodies Research. A notable 1983 paper examined how cholesterol-free phospholipid domains may be selected by Nε-dansyl-L-lysine and merocyanine 540.

How has patent activity involving Dns-lysine changed in recent years?

Patent filings have shown fluctuation, with 13 patents in 2022 representing the peak in the last decade. Activity in 2023 was 11 patents, declining to 8 in 2024 and 2 in 2025. No papers have been published in the last three years, though 29 papers are documented in the full archive.

Turn any compound into a complete chemical intelligence landscape

Go beyond static compound data. Cypris resolves identities, patents, papers, and commercial signals into one AI-powered view - so your team can move from a single chemical question to a complete R&D, IP, and market landscape.

Schedule a free trial